Macitentan
Most-read FDA actions from 2024 in pulmonology
Healio Pulmonology has compiled the top news from the FDA posted in 2024.
96% of patients with PAH prefer a single-tablet combination therapy
When presented with four unlabeled treatment profiles showing five treatment attributes, 96% of patients with pulmonary arterial hypertension chose a single-tablet vs. a multi-tablet combination therapy, according to a poster.
Combination macitentan, tadalafil tablet improves exercise capacity in PAH
SAN DIEGO — Exercise capacity improved among adults with pulmonary arterial hypertension taking a macitentan-tadalafil tablet over 68 weeks, according to research presented at the American Thoracic Society International Conference.
FDA approves combination therapy tablet for pulmonary arterial hypertension
The FDA has approved Opsynvi, a once-daily tablet that includes both macitentan and tadalafil, to treat adults with pulmonary arterial hypertension, according to a manufacturer-issued press release.
Combination therapy in patients with new pulmonary arterial hypertension often delayed
WASHINGTON — Only 8% of patients with pulmonary arterial hypertension initiating combination therapy were given both medications on the same day, according to research presented at the American Thoracic Society International Conference.
Macitentan demonstrates safety in real-world patients with pulmonary arterial hypertension
Initial triple therapy vs. double may improve outcomes in newly diagnosed PAH: TRITON
In patients with newly diagnosed pulmonary arterial hypertension, initial triple oral therapy, compared with double therapy, both improved hemodynamics, NT-proBNP and functional capacity, with no difference between strategies at 26 weeks.